维普期刊资源整合服务平台（V6.5）

26篇 您的检索式：作者名="Bugelski"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	A novel EPO receptor agonist improves glucose tolerance via glucose uptake in skeletal muscle in a mouse model of diabetes显示文摘	Scully M S Ort T A James I E Bugelski P J Makropoulos D A Deutsch H A	2011	Exp Diabetes Res2011，，91：	1
2	Autoradiographic distribution of HPD in normal and tumor tissue of the mouse显示文摘	Bugelski PJ Porter CW Dougherty TJ	1981	Cancer Res1981，41，111：	1
3	A strategy for primary high throughput cytotoxicity screening in pharmaceutical toxicology显示文摘	Bugelski PJ Atif U Molton S	2000	Pharm Res2000，17，10：	1
4	A strategy for primary high throughput cytotoxicity in pharmaceutical toxicology 显示文摘	BUGELSKI PJ ATIF U MOLTONS	2000	Pharm Res2000，17，10：	1
5	Interference with Tissue Factor Prolongs Intrahepatic Islet Allograft Survival in a Nonhuman Primate Marginal Mass Model显示文摘	Dora M. Berman Over Cabrera Norman M. Kenyon Joshua Miller Susan H. Tam Vrinda S. Khandekar Kristen M. Picha Avery R. Soderman Robert E. Jordan Peter J. Bugelski Denison Horninger Michael Lark Janet E. Davis Rodolfo Alejandro Per-Olof Berggren Mark Zimmer	2007	Transplantation2007，，3：	1
6	Genetic aspects of immune-mediated adverse drug effects显示文摘	Bugelski PJ	2005	Nat Rev Drug Discov2005，4，1：	1
7	Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans 显示文摘	BUGELSKI PJ TREACY G	2004	Curr Opin Mol Ther2004，6，1：	1
8	Temporal relation between neutrophil accumulation and myocardial reperfusion injury显示文摘	Smith EF 3rd Egan JW Bugelski PJ		0，，5：	1
9	T-dependent antigen response (TDAR)tests: meta-analysis of results generated across multiplelaboratories 显示文摘	Bugelski PJ Kim C	2007	JImmunotoxicoU2007，4，2：	1
10	Preclinical safety of recombinant human interleukin-18显示文摘	Herzyk DJ Bugelski PJ Hart TK		0，，05：	1
11	Concordance Concordance of preclini- cal and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets显示文摘	Martin PL Bugelski PJ	2012	Br J Phar- macol2012，166，3：	1
12	Preclinical safety of recombinant human interleukin-18显示文摘	Herzyk DJ Bugelski PJ Hart TK	2003	Toxicol Pathol2003，31，5：	1
13	Genetic aspects of immune-mediated adverse drug effects显示文摘	Bugelski PJ	2005	Nat Rev Drug Discov2005，4，1：	1
14	Temporal relation between neutrophil accumulation and myocardial reperfusion injury显示文摘	Engan JW Bugelski PJ	1998	Am J Physiol1998，255，：	1
15	Preclinical development of keliximab, a Primatized anti-CD4 monoclonal antibody, in human CD4 transgenic mice: characterization of the model and safety studies 显示文摘	Bugelski PJ Herzyk DJ Rehm S	2000	Hum Exp Toxicol2000，19，4：	1
16	ARDS-like lung injury produced by endotoxin in platelet-activating factor-primed rats 显示文摘	Rabinovici R Bugelski PJ Esser KM	1993	J Appl Physiol1993，74，4：	1
17	Presentation time,total time,and mediation in paired associate learning显示文摘	Bugelski B R		0，，：	1
18	T-dependent antigen response (TDAR)tests: meta-analysis of results generated across multiplelaboratories 显示文摘	Bugelski PJ Kim C	2007	JImmunotoxicoU2007，4，2：	1
19	Autoxadiographic distribution of hematoporphyrin derivative in normal and tumor tissue of the mouse显示文摘	Bugelski PJ Porter CW Dougherty TJ	1981	Cancer Res1981，41，11：	1
20	T-dependent antigen response(TDAR) tests: meta-analysis of results generated across multiple laboratories 显示文摘	BUGELSKI PJ KIM C	2007	J Immunotoxicol2007，4，2：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示